Related Experiment Video
Updated: Sep 23, 2025
13:18
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.4K
NF-κB-Activated lncRNACASC9 Promotes Bladder Cancer Progression by Regulating the TK1 Expression
Cai Longjun1,2, Zhang Jianjun2, Pang Kun1,3
1Medical College of Soochow University, Suzhou, 215123 Jiangsu, China.
Journal of Oncology
|May 17, 2022
Summary
Long noncoding RNA CASC9 (lncRNACASC9) promotes bladder cancer growth and metastasis. This study reveals the CASC9/miR-195-5p/TK1 pathway as a key driver in bladder cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Long noncoding RNAs (lncRNAs) are implicated in cancer, yet their specific roles in bladder cancer remain largely unknown.
- Identifying novel molecular players is crucial for understanding bladder cancer pathogenesis and developing targeted therapies.
Purpose of the Study:
- To identify aberrantly expressed lncRNAs in bladder cancer.
- To investigate the functional role and underlying mechanism of lncRNACASC9 in bladder cancer progression.
Main Methods:
- Analysis of lncRNA expression in bladder cancer tissues and cells.
- In vitro assays (colony formation, CCK-8, EdU, Transwell) and in vivo models (xenograft, metastasis).
- Molecular mechanism studies including FISH, luciferase reporter assays, and RIP assays.
Main Results:
- lncRNACASC9 was significantly upregulated in bladder cancer tissues and associated with poor patient prognosis.
- lncRNACASC9 promoted bladder cancer cell proliferation, migration, and invasion in vitro and in vivo.
- CASC9 acts as an oncogene by sponging miR-195-5p to upregulate TK1 expression.
Conclusions:
- The CASC9/miR-195-5p/TK1 axis is a critical oncogenic pathway in bladder cancer.
- lncRNACASC9 represents a potential therapeutic target for bladder cancer treatment.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
02:26NF-κB-dependent Signaling Pathway
7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.9K
01:07MAPK Signaling Cascades
6.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.3K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K